Open AccessSevere infusion reaction due to nivolumab: A case report
Author(s) -
Kumari Seema,
Yun James,
Soares James R.,
Ding Pei N.
Publication year - 2020
Publication title -
cancer reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 5
ISSN - 2573-8348
DOI - 10.1002/cnr2.1246
Subject(s) - nivolumab , medicine , lung cancer , cancer , intensive care medicine , oncology , immunotherapy
Background Nivolumab is an anti‐PD1 immune checkpoint inhibitor commonly used for the treatment of solid organ and hematological malignancies. Severe infusion reaction due to nivolumab is quite rare. Case We report a case of severe infusion reaction due to nivolumab necessitating ICU admission and withdrawal of further nivolumab use in a patient with metastatic non‐small cell lung cancer. Conclusion Our knowledge and expertise with the use of immune checkpoint inhibitors are still evolving. This report highlights one of the rare possible side‐effects that clinicians and patients may have to face with increasing indications and use of nivolumab in day to day practice.